微小RNA与乳腺癌

doi:10.3760/cma.j.issn.1673-422X.2014.01.012

摘要/Abstract

摘要： 微小RNA（miRNA）是一类小分子的非编码RNA，已发现这类RNA在乳腺癌中可扮演癌基因和抑癌基因的角色，在肿瘤侵袭转移级联反应各阶段也起到促进或者抑制作用，与肿瘤的上皮间质转化及肿瘤干细胞的生成也高度相关。最新研究表明，miRNA可作为肿瘤诊断预后的一项重要指标，为靶向miRNA生物治疗方式作用于乳腺癌临床诊断治疗提供了理论依据。

关键词: 微RNAs, 乳腺肿瘤, 肿瘤转移, 诊断, 分子靶向治疗

Abstract: MicroRNAs (miRNAs) are a class of small molecule noncoding RNAs. Those RNAs are considered as oncogenes and tumor suppressor genes in breast cancer and can be a promoter or inhibitor in tumor invasion and metastasis cascade stages, and they are also closely related to the tumor epithelialmesenchymal transition and tumor stem cell generation. New researches show that miRNAs can serve as significant diagnostic and prognostic indicators to provide a theoretical basis for the biotherapy of targeting miRNAs which is applied to the clinical diagnosis and treatment of breast cancer.

Key words: MicroRNAs, Breast neoplasms, Neoplasm metastasis, Diagnosis, Molecular targeted therapy

张婷婷, 刘勇军, 梁爱玲. 微小RNA与乳腺癌[J]. 国际肿瘤学杂志, 2014, 41(1): 37-40.

Zhang Tingting, Liu Yongjun, Liang Ailing. MicroRNAs and breast cancer[J]. Journal of International Oncology, 2014, 41(1): 37-40.

参考文献

［1］ Zhang B, PanX, Cobb G, et al. MicroRNAs as oncogenes and tumor suppressors［J］. Dev Biol, 2007, 302(1):112. ［2］ Manikandan J, Aarthi JJ, Kumar SD, et al. Oncomirs: the potential role of noncoding microRNAs in understanding cancer［J］. Bioinformation, 2008, 2(8):330334. ［3］ Connolly EC, Van Doorslaer K, Rogler LE, et al. Overexpression of miR21 promotes an in vitro metastatic phenotype by targeting the tumor suppressor RHOB［J］. Mol Cancer Res, 2010, 8(5):691700. ［4］ Meng F, Henson R, Lang M, et al. Involvement of human microRNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines［J］. Gastroenterology, 2006, 130(7):21132129. ［5］ Zhu S, Si ML, Wu H, et al. MicroRNA21 targets the tumor suppressor gene tropomyosin 1 (TPM1)［J］. J Biol Chem, 2007, 282(19):1432814336. ［6］ Zhu, S, Wu H, Wu F, et al. MicroRNA21 targets tumor suppressor genes in invasion and metastasis［J］. Cell Res, 2008, 18(3):350359. ［7］ Shah MY, Calin GA. MicroRNAs miR221 and miR222: a new level of regulation in aggressive breast cancer［J］. Genome Med, 2011, 3(8):56. ［8］ Li J, Kong X, Zhang J, et al. Correction: miRNA26b inhibits proliferation by targeting PTGS2 in breast cancer［J］. Cancer Cell Int, 2013, 13(1):17. ［9］ Taube JH, Herschkowitz JI, Komurov K, et al. Core epithelialtomesenchymal transition interactome geneexpression signature is associated with claudinlow and metaplastic breast cancer subtypes［J］. Proc Natl Acad Sci USA, 2010, 107(35):1544915454. ［10］ Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer［J］. Oncogene, 2010, 29(34):47414751. ［11］ Liang YJ, Wang QY, Zhou CX, et al. MiR124 targets Slug to regulate epithelialmesenchymal transition and metastasis of breast cancer［J］. Carcinogenesis, 2013, 34(3):713722. ［12］ Stinson S, Lackner MR, Adai AT, et al. MiR221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelialtomesenchymal transition in breast cancer［J］. Sci Signal, 2011, 4(186):pt5. ［13］ Han M, Liu M, Wang Y, et al. Reexpression of miR21 contributes to migration and invasion by inducing epithelialmesenchymal transition consistent with cancer stem cell characteristics in MCF7 cells［J］. Mol Cell Biochem, 2012, 363(12):427436. ［14］ Schwarzenbacher D, Balic M, Pichler M. The role of microRNAs in breast cancer stem cells［J］. Int J Mol Sci, 2013, 14(7):1471214723. ［15］ Liu S, Patel SH, Ginestier C, et al. MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells［J］. PLoS Genet, 2012, 8(6):e1002751. ［16］ Qian B, Katsaros D, Lu L, et al. High miR21 expression in breast cancer associated with poor diseasefree survival in early stage disease and high TGFbeta1［J］. Breast Cancer Res Treat, 2009, 117(1):131140. ［17］ Wu ZS, Wu Q, Wang CQ, et al. MiR340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein cMet［J］. Cancer, 2011, 117(13): 28422852. ［18］陈晓兰，秦树佩，杨建新. 微小RNA与乳腺癌细胞的增殖与转移［J］. 国际肿瘤学杂志, 2012， 39(4): 265268. ［19］ Ma L, TeruyaFeldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA10b in breast cancer［J］. Nature, 2007, 449(7163): 682688. ［20］ Sun Y, Wang M, Lin G, et al. Serum microRNA155 as a potential biomarker to track disease in breast cancer［J］. PLoS One, 2012, 7(10):e47003. ［21］ Lu Z, Ye Y, Jiao D, et al. MiR155 and miR31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status［J］. Oncol Lett, 2012, 4(5):10271032. ［22］ Wang H, Tan G, Dong L, et al. Circulating miR125b as a marker predicting chemoresistance in breast cancer［J］. PLoS One, 2012, 7(4):e34210. ［23］ Liu Y, Zhao J, Zhang PY, et al. MicroRNA10b targets Ecadherin and modulates breast cancer metastasis［J］. Med Sci Monit, 2012, 18(8):BR299308. ［24］ Li J, Shen L, Xiao XG, et al. MicroRNAs in breast cancer and breast cancer stem cells and their potential for breast cancer therapy［J］. Chin Med J (Engl), 2013, 126(13):25562563. ［25］ Kota J, Chivukula RR, O′Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model［J］. Cell, 2009, 137(6):10051017. ［26］ Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells［J］. Nat Methods, 2007, 4(9):721726. ［27］ Ma L, Young J, Prabhala H, et al. MiR9, a MYC/MYCNactivated microRNA, regulates Ecadherin and cancer metastasis［J］. Nat Cell Biol, 2010, 12(3):247256.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[3]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[4]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.
[5]	陈琦, 徐晨阳, 王寅, 雷大鹏. 高光谱成像在头颈部肿瘤诊疗中的应用现状[J]. 国际肿瘤学杂志, 2024, 51(5): 298-302.
[6]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[7]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[8]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[9]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[10]	张丽丽, 谭茹, 房雪利, 杨宇, 桑铮, 李宝生. 乳腺导管原位癌影像学诊断、病理学升级及影像学技术进展[J]. 国际肿瘤学杂志, 2024, 51(3): 166-169.
[11]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[12]	彭琴, 蔡玉婷, 王伟. KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[13]	龚艳, 陈洪雷. 微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190.
[14]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[15]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.